Wall Street Zen cut shares of Sionna Therapeutics (NASDAQ:SION - Free Report) from a hold rating to a sell rating in a research note issued to investors on Thursday.
Other equities analysts also recently issued reports about the company. TD Cowen assumed coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating for the company. Stifel Nicolaus started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a "buy" rating and a $32.00 price objective for the company. Finally, Guggenheim started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a "buy" rating and a $45.00 price objective for the company.
Check Out Our Latest Research Report on SION
Sionna Therapeutics Stock Up 2.8%
SION stock traded up $0.35 during midday trading on Thursday, reaching $13.07. The company had a trading volume of 51,961 shares, compared to its average volume of 188,933. The stock's 50 day moving average price is $11.72. Sionna Therapeutics has a fifty-two week low of $7.26 and a fifty-two week high of $25.19.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.17).
Hedge Funds Weigh In On Sionna Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Zimmer Partners LP acquired a new position in shares of Sionna Therapeutics during the first quarter worth approximately $2,484,000. Alyeska Investment Group L.P. acquired a new position in shares of Sionna Therapeutics during the first quarter worth approximately $1,948,000. Charles Schwab Investment Management Inc. bought a new stake in Sionna Therapeutics during the first quarter worth approximately $676,000. RA Capital Management L.P. bought a new stake in Sionna Therapeutics during the first quarter worth approximately $109,258,000. Finally, Baker BROS. Advisors LP bought a new stake in Sionna Therapeutics during the first quarter worth approximately $4,184,000.
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Stories
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
